SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Durrant J. R.)
 

Sökning: WFRF:(Durrant J. R.) > The TRAIL system is...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003417naa a2200409 4500
001oai:DiVA.org:uu-247382
003SwePub
008150318s2015 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2473822 URI
024a https://doi.org/10.1007/s00432-014-1822-02 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Ullenhag, Gustav J.u Uppsala universitet,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)gustulle
2451 0a The TRAIL system is over-expressed in breast cancer and FLIP a marker of good prognosis
264 c 2014-09-18
264 1b Springer Science and Business Media LLC,c 2015
338 a print2 rdacarrier
520 a Background Breast cancer is the most common cancer in women. The tumor necrosis factor-related apoptosisinducing ligand (TRAIL) pathway transmits apoptotic signals. Novel anticancer agents that activate this system are in clinical development, including anti-breast cancer. Methods The tissue microarray technique was applied. We used an array of breast cancer tissues from a large group of patients (> 800) to assess the protein expression of TRAIL-R1, TRAIL-R2, the long isoform of FLICE-inhibitory protein and total FLICE-inhibitory protein (FLIPL and FLIPT). Disease-free survival was examined by Kaplan-Meier estimates and the log-rank test. The independence of prognostic factors was determined by Cox multivariate analysis. Results High intra-tumoral expression of all these proteins of the TRAIL pathway was found. The TRAIL receptors and FLIPL were not associated with survival. On univariate analysis, strong FLIPT expression was associated with a significantly better survival (p = 0.001). On multivariate analysis using the Cox proportional hazards model, FLIPT phenotype was significantly associated with a good prognosis in this series (HR 0.52, 95 % CI 0.35-0.78, p = 0.039). Results indicate that this association is valid for all the biological subtypes of breast cancer. The expression of FLIPT was especially high in the luminal subtype, known for its good prognosis. Conclusions These findings support the use of agonistic TRAIL antibodies and drugs targeting FLIP in breast cancer patients. Over-expression of FLIPT but not TRAIL-R1, TRAIL-R2 or FLIPL provides stage-independent prognostic information in breast cancer patients. This indicates a clinically less aggressive phenotype.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Breast cancer
653 a Tissue microarray
653 a Prognostic factor
653 a TRAIL-R
653 a FLIP
700a Al-Attar, Ahmad4 aut
700a Mukherjee, Abhik4 aut
700a Green, Andrew R.4 aut
700a Ellis, Ian O.4 aut
700a Durrant, Lindy G.4 aut
710a Uppsala universitetb Experimentell och klinisk onkologi4 org
773t Journal of Cancer Research and Clinical Oncologyd : Springer Science and Business Media LLCg 141:3, s. 505-514q 141:3<505-514x 0171-5216x 1432-1335
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-247382
8564 8u https://doi.org/10.1007/s00432-014-1822-0

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy